Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.07.20.213249: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Serum Samples: Serum samples for sensitivity analyses were obtained from Great Ormond Street Children’s Hospital NHS Foundation Trust (GOSH) and came from three sources; (i) healthcare workers who tested SARS-CoV-2 RT-PCR positive following signs or symptoms of COVID-19 and who gave written consent for participation in the service evaluation of SARS-CoV-2 serological assays, (ii) staff enrolling in a prospective longitudinal cohort study of SARS-CoV-Serology (COSTARS, IRAS 282713, ClinicalTrials.gov Identifier: NCT04380896) who tested positive in a commercial screening assay for anti-Nucleocapsid IgG (Epitope Diagnostics Inc, San Diego, USA) (iii) a … SciScore for 10.1101/2020.07.20.213249: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Serum Samples: Serum samples for sensitivity analyses were obtained from Great Ormond Street Children’s Hospital NHS Foundation Trust (GOSH) and came from three sources; (i) healthcare workers who tested SARS-CoV-2 RT-PCR positive following signs or symptoms of COVID-19 and who gave written consent for participation in the service evaluation of SARS-CoV-2 serological assays, (ii) staff enrolling in a prospective longitudinal cohort study of SARS-CoV-Serology (COSTARS, IRAS 282713, ClinicalTrials.gov Identifier: NCT04380896) who tested positive in a commercial screening assay for anti-Nucleocapsid IgG (Epitope Diagnostics Inc, San Diego, USA) (iii) a small number of RT-PCR positive sera from hospitalised children ( Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources This serum was calibrated against research reagents NIBSC 20/130 and NIBSC 20/124 distributed by the National Institute for Standards and Biological Control (NIBSC, Potters Bar, UK, https://www.nibsc.org/) for the purpose of development and evaluation of serological assays for the detection of antibodies against SARS-CoV-2. SARS-CoV-2suggested: NoneAfter incubation for 2 hours with shaking at 700rpm, the plates were washed three times and detection antibody was added at 2 µg/mL (MSD SULFO-TAG™ Anti-Human IgG Antibody). Anti-Human IgGsuggested: NoneSoftware and Algorithms Sentences Resources Statistical analysis: Statistical analysis was performed using MSD Discovery Workbench and GraphPad Prism version 8.0 (GraphPad, San Diego, CA) GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04380896 Recruiting COVID-19 Staff Testing of Antibody Responses Study (Co-Stars… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
